Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

2008 • 25,031 citations

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

2000 • 15,583 citations

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

2010 • 14,016 citations

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

2011 • 7,390 citations

Final Version of 2009 AJCC Melanoma Staging and Classification

2009 • 4,457 citations

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

2011 • 4,304 citations

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

2010 • 3,500 citations

Prognostic and Clinicopathologic Associations of Oncogenic BRAF in Metastatic Melanoma

2011 • 976 citations

Selective BRAFV600E Inhibition Enhances T-Cell Recognition of Melanoma without Affecting Lymphocyte Function

2010 • 703 citations

The BRAF–MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells

2006 • 647 citations

B-RAF is a therapeutic target in melanoma

2004 • 435 citations

Predictors of Competing Mortality in Advanced Head and Neck Cancer

2009 • 432 citations

Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors.

2010 • 278 citations

Cutaneous melanoma

2005 • 256 citations

Role of the Mitogen-Activated Protein Kinase Signaling Pathway in the Regulation of Human Melanocytic Antigen Expression

2006 • 140 citations

The Oncogenic BRAF Kinase Inhibitor PLX4032/RG7204 Does Not Affect the Viability or Function of Human Lymphocytes across a Wide Range of Concentrations

2010 • 139 citations

Cutaneous melanoma in the era of molecular profiling

2009 • 129 citations

Favorable outcome in clinically stage II melanoma patients is associated with the presence of activated tumor infiltrating T‐lymphocytes and preserved MHC class I antigen expression

2008 • 126 citations

Treatment combinations targeting apoptosis to improve immunotherapy of melanoma

2009 • 38 citations

Morphologic and immunohistochemical (IHC) changes in metastatic melanoma (MM) tissue and associations with clinical outcome in patients (pts) on BRAF inhibitors (BRAFi).

2011 • 6 citations